Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for treatment of RA. We compared tofacitinib modified-release (MR) 11 mg once daily (QD) with tofacitinib immediate-release (IR) 5 mg twice daily (BID) in Japanese patients with RA and inadequate response to MTX. METHODS: Phase III, randomized...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Rheumatology (Oxford)
Egile Nagusiak: Tanaka, Yoshiya, Sugiyama, Naonobu, Toyoizumi, Shigeyuki, Lukic, Tatjana, Lamba, Manisha, Zhang, Richard, Chen, Connie, Stock, Thomas, Valdez, Hernan, Mojcik, Christopher, Fan, Haiyun, Deng, Chenhui, Yuasa, Hirotoshi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Clinical Science
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6293484/
https://ncbi.nlm.nih.gov/pubmed/30137547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/rheumatology/key250
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak